The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
“If the short history of telematics in the auto insurance taught us anything, it’s to be skeptical of any promises attached to shareable surveillance data.”
A CMS rule finalized this week may prove more difficult to challenge than previous Trump administration actions to end transgender care for young people.
Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each
When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.
One way to fight medical misinformation: make it easier for people to understand when they are being manipulated, write Paul Martin Jensen and Avi Tuschman.
Talks are underway between the Democratic Republic of the Congo and the WHO to expedite the start of a multi-armed Phase 3 clinical trial of Ebola vaccines.
The White House's order attempting to overhaul the vaccine schedule could subject children to more needles and more disease risk, world health leaders say.
A newly approved drug for Prader-Willi syndrome, a rare disease that causes an insatiable desire to eat, may be tied to a series of patient deaths, experts say.
Medicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.
The Trump administration, which had recently avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.
A Tenax Therapeutics drug designed to treat a type of heart failure associated with high blood pressure in the lungs failed in a closely watched study.
“To blame Fauci for not solving the origin of Covid-19 makes as much sense as blaming a detective in Washington, D.C., for not solving a murder in Wuhan,” writes David…
The NIH plans to close the door on one of the few pathways available to international students on visas to forge a career in biomedical research in the U.S.
A little-noticed government policy shift caused a seven-year delay in choosing a costly medicine for Medicare price negotiations, an advocacy group says.
The protein tau is top target for Alzheimer’s drug development, and a new study bolsters those efforts by describing a previously unknown role that tau plays in neurodegeneration.
The U.S. moves to shut a Kentucky organ donation group that's been accused of continuing plans for organ retrieval from some patients who unexpectedly showed signs of life.
“A transparent evaluation of Covid would separate what happened from competing political narratives and help us improve for the future,” writes IDSA President Ronald Nahass.
Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.
The FDA approved a novel type of treatment for narcolepsy made by Takeda, backing a new drug class that scientists hope can be used to treat other conditions.
With a second delayed report of a child's death in China, criticism is rising of a looser form of clinical trial. One expert: what "bothers me is the lack of…
The Senate investigation includes RFK Jr. as well as the heads of Reynolds American and kratom company Botanic Tonics, asking for written responses and documentation by Aug. 31.
Excluding rare disease therapies from a Medicare pilot program to lower drug prices would wipe out much of the savings from retail drugs, according to new research.
Pre-biopsy MRI is standard outside the U.S., but the latest data show such scans were done in only about a third of U.S. prostate cancer cases in 2022.
